Whoop and Oura Becoming Clinical Devices
$1.1B/year Under Armour of health wearables
The real prize is no longer fitness coaching, it is clinical grade health data that can be used in care, underwriting, and drug targeting. Whoop and Oura started from different habits, wrist recovery for athletes versus ring based sleep tracking, but both are now shipping the same stack of higher value features, including AFib related monitoring, cycle insights, and blood pressure programs, while pairing consumer subscriptions with healthcare relationships and richer longitudinal records.
-
Whoop has moved furthest toward regulated health tooling. Its March 31, 2026 Series G announcement describes an FDA cleared ECG, Blood Pressure Insights, Advanced Labs blood biomarker analysis, and strategic backing from Abbott and Mayo Clinic. That pushes Whoop beyond training readiness into a clinical workflow adjacent product.
-
Oura is building toward the same endpoint from a different body location and user base. Oura has scaled from $225M revenue in 2023 to $1B in 2025, added cycle and pregnancy features, is running a blood pressure study, and partnered with Dexcom so glucose data sits next to sleep, stress, heart, and activity data in one app.
-
Apple validates the category, but its product is still a broad watch computer, not a dedicated health subscription. Apple supports ECG and AFib history, and added hypertension notifications on Series 11, yet its model is device first. Whoop and Oura are building recurring member relationships around health behavior and continuous data capture.
The next phase is a race to become the consumer health system of record outside the hospital. The winner will not just sell a wearable, it will combine passive sensor data, lab data, and condition specific coaching into something insurers, employers, providers, and pharma can plug into as a living longitudinal file.